Development and validation of a sensitive LC-MS/MS method for pioglitazone: application towards pharmacokinetic and tissue distribution study in rats

Kumari, Garikapati Kusuma; Krishnamurthy, Praveen Thaggikuppe; Ammu, V.V.V. Ravi Kiran; Kurawattimath, Vishwanath; Narenderan, S. T.; Babu, B.; Nagappan, Krishnaveni

doi:10.1039/d1ra01126j

Cited by 10 publications

(2 citation statements)

References 34 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study was conducted at the in‐house animal facility of JSS College of Pharmacy, Ooty, India, in accordance with the guidelines and approval of the Institutional Animal Ethics Committee (IAEC) (approval number: JSSCP/OT/IAEC/13/2019‐20). The protocol for drug administration and blood collection was performed as in our previous study/report (G. et al, 2021). Briefly, 18 overnight‐fasted male Wistar rats were orally administered 10 mg/kg of rosiglitazone.…”

Section: Methodsmentioning

confidence: 99%

“…Because of the increasing availability of sufficient sensitive tandem mass spectrometers, quantification of antidiabetic drugs via LC–MS/MS methodologies has been increasing due to their wide range, great accuracy, and high specificity. Thus far, few methods have been developed and utilized for the quantification of rosiglitazone in blood plasma and urine samples of rats, dogs, and humans utilizing various analytical techniques such as HPLC, LC–MS, capillary electrophoresis (CZE), and UV derivative spectroscopy detection methods (Doomkaew et al, 2015; El‐Enany et al, 2012; G. et al, 2021; Lakshmi & Rajesh, 2010; Mamidi et al, 2011; O'Maille et al, 2008; Pedersen et al, 2005; Ramesh et al, 2015). Although many analytical methods were developed for quantifying rosiglitazone, none of these have been carried out in tissues such as brain, bone, heart, and kidney, as a measure of off‐target side effects of rosiglitazone.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Quantification of rosiglitazone in rat plasma and tissues via LC–MS/MS: Method development, validation, and application in pharmacokinetic and tissue distribution studies

Garikapati

Kiran

Krishnamurthy

et al. 2022

Biomedical Chromatography

Self Cite

View full text Add to dashboard Cite

A bioanalytical method for the quantification of rosiglitazone in rat plasma and tissues (adipose tissue, heart, brain, bone, and kidney) using LC–MS/MS was developed and validated. Chromatographic separation was achieved on a Gemini C18 column (50 × 4.6 mm, 3 μm) using a mobile phase consisting of 10 mM ammonium formate (pH 4.0) and acetonitrile (10:90, v/v) at a flow rate of 0.8 mL/min and injection volume of 10 μL (internal standard: pioglitazone). LC–MS detection was performed with multiple reaction monitoring mode using target ions at m/z → 358.0 and m/z → 357.67 for rosiglitazone and pioglitazone (internal standard), respectively. The calibration curve showed a good correlation coefficient (r2) over the concentration range of 1–10,000 ng/mL. The mean percentage recoveries of rosiglitazone were found to be over the range of 92.54–96.64%, with detection and lower quantification limit of 0.6 and 1.0 ng/mL, respectively. The developed method was validated per U.S. Food and Drug Administration guidelines and successfully utilized to measure rosiglitazone in plasma and tissue samples. Further, the developed method can be utilized for validating specific organ‐targeting delivery systems of rosiglitazone in addition to conventional dosage forms.

show abstract

Section: Methodsmentioning

confidence: 99%